These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33153631)

  • 1. Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure.
    Secora AM; Shin JI; Qiao Y; Alexander GC; Chang AR; Inker LA; Coresh J; Grams ME
    Mayo Clin Proc; 2020 Nov; 95(11):2408-2419. PubMed ID: 33153631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
    Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
    J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
    Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
    Berry C; McMurray JJ
    Heart; 2001 Apr; 85(4):E8. PubMed ID: 11250985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperkalemia during spironolactone use in patients with decompensated heart failure.
    Lima MV; Ochiai ME; Cardoso JN; Morgado PC; Munhoz RT; Barretto AC
    Arq Bras Cardiol; 2008 Sep; 91(3):177-82, 194-9. PubMed ID: 18853060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone in chronic hemodialysis patients improves cardiac function.
    Taheri S; Mortazavi M; Shahidi S; Pourmoghadas A; Garakyaraghi M; Seirafian S; Eshaghian A; Ghassami M
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):392-7. PubMed ID: 19414940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.
    Cavallari LH; Groo VL; Viana MA; Dai Y; Patel SR; Stamos TD
    Pharmacotherapy; 2010 Jan; 30(1):1-9. PubMed ID: 20030467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race influences the safety and efficacy of spironolactone in severe heart failure.
    Vardeny O; Cavallari LH; Claggett B; Desai AS; Anand I; Rossignol P; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2013 Sep; 6(5):970-6. PubMed ID: 23940307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.
    Hu Y; Carpenter JP; Cheung AT
    Anesth Analg; 2002 Jul; 95(1):39-41, table of contents. PubMed ID: 12088939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
    Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
    J Card Fail; 2004 Aug; 10(4):297-303. PubMed ID: 15309695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction.
    Wang TY; Vora AN; Peng SA; Fonarow GC; Das S; de Lemos JA; Peterson ED
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26796254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure.
    Allen LA; Shetterly SM; Peterson PN; Gurwitz JH; Smith DH; Brand DW; Fairclough DL; Rumsfeld JS; Masoudi FA; Magid DJ
    Circ Heart Fail; 2014 Jan; 7(1):43-50. PubMed ID: 24281136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
    Muzzarelli S; Maeder MT; Toggweiler S; Rickli H; Nietlispach F; Julius B; Burkard T; Pfisterer ME; Brunner-La Rocca HP;
    Am J Cardiol; 2012 Mar; 109(5):693-8. PubMed ID: 22152974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries.
    Desai RJ; Solomon SD; Vaduganathan M
    J Card Fail; 2022 Jun; 28(6):1035-1039. PubMed ID: 35114384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone for heart failure with preserved ejection fraction.
    Pitt B; Pfeffer MA; Assmann SF; Boineau R; Anand IS; Claggett B; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Harty B; Heitner JF; Kenwood CT; Lewis EF; O'Meara E; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; Yang S; McKinlay SM;
    N Engl J Med; 2014 Apr; 370(15):1383-92. PubMed ID: 24716680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapy update. Inspra (eplerenone tablets).
    Kloner RA
    Congest Heart Fail; 2003; 9(6):341-2. PubMed ID: 14688507
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.